|
2024
|
Invention
|
Combination therapy with axl inhibitor and immune checkpoint modulator or oncolytic virus.
The p... |
|
2023
|
Invention
|
Anti-axl antagonistic antibodies.
The present disclosure relates to antibodies that specifically... |
|
|
Invention
|
Dosage regimen for axl inhibitor. This disclosure relates to compositions and methods for treatin... |
|
|
Invention
|
Anti-axl antagonistic antibodies.
Described are antibodies that specifically bind to the Axl pro... |
|
2022
|
Invention
|
Combination of axl antibodies and ace inhibitors in the treatment of fibrosis.
This disclosure r... |
|
|
Invention
|
Combination of axl antibodies and ace inhibitors in the treatment of fibrosis. This disclosure re... |
|
|
G/S
|
Pharmaceutical preparations for the treatment of cancer and severe respiratory infections; pharma... |
|
|
G/S
|
Pharmaceutical preparations; veterinary preparations;
pharmaceuticals, medical and veterinary pr... |
|
2021
|
Invention
|
Anti-axl antagonistic antibodies. The present disclosure relates to antibodies that specifically ... |
|
|
G/S
|
Chemical preparations, chemical compounds, biochemical preparations and biologic compounds for sc... |
|
|
G/S
|
Chemicals, chemical compounds, biochemicals and biologic compounds for scientific and industrial ... |
|
|
G/S
|
Chemicals, chemical compounds, biochemicals and biologic
compounds for scientific or industrial ... |
|
|
Invention
|
Anti-axl antibodies.
Antibodies which specifically bind to the Axl protein are described. Also d... |
|
|
Invention
|
Humanized anti-axl antibodies.
The present disclosure relates to humanized anti-Axl antibodies. |
|
|
Invention
|
Method of selecting patients for treatment with a combination of an axl inhibitor and an immune c... |
|
|
Invention
|
Axl inhibitors for antiviral therapy.
This disclosure relates to compostions and methods for pre... |
|
|
Invention
|
Axl inhibitors for antiviral therapy. This disclosure relates to compostions and methods for prev... |
|
|
Invention
|
Combination therapy comprising an axl inhibitor.
This disclosure relates to a combination therap... |
|
|
Invention
|
Combination therapy comprising an axl inhibitor. This disclosure relates to a combination therapy... |
|
2020
|
Invention
|
Combination therapy of a patient subgroup. This disclosure relates to methods of treating a defin... |
|
|
Invention
|
Pharmaceutically active compounds.
The invention is directed to compounds of general formula (I)... |
|
|
Invention
|
Combination therapy with axl inhibitor and immune checkpoint modulator or oncolytic virus. An Axl... |
|
2019
|
Invention
|
Pharmaceutically active compounds. The invention is directed to compounds of general formula (I)
... |
|
|
Invention
|
Serum biomarkers.
The present disclosure relates to the field of cancer biomarkers and treatment... |
|
|
Invention
|
Serum biomarkers. The present disclosure relates to the field of cancer biomarkers and treatments... |
|
|
Invention
|
Method.
The use of Akt3 as a biomarker for detecting the occurrence of epithelial-to-mesenchymal... |
|
2018
|
Invention
|
Anti-axl antagonistic antibodies. Described are antibodies that specifically bind to the Axl prot... |
|
|
Invention
|
Anti-axl antibodies. Antibodies which specifically bind to the Axl protein are described. Also di... |
|
2016
|
Invention
|
Biomarkers for cancer. The use of PHGDH as a biomarker for detecting the occurrence of epithelial... |
|
|
Invention
|
Combination therapy with axl inhibitor and immune checkpoint modulator or oncolytic virus.
An Ax... |
|
|
Invention
|
Combination therapy with axl inhibitor and immune checkpoint modulator or oncolytic virus. The pr... |
|
|
Invention
|
Humanized anti-axl antibodies. The present disclosure relates to humanized anti-Axl antibodies. |
|
2015
|
Invention
|
Pharmaceutically active compounds. The invention is directed to compounds of general formula (I),... |
|
|
Invention
|
Inhibitors of akt kinase. The invention is directed to compounds of general formula (I), and phar... |
|
|
Invention
|
Process for the purification of the axl tyrosine receptor kinase inhibitor “r428”. 3-(7-(pyrrolid... |
|
|
Invention
|
Slfn11 as biomarker for aml.
The use of Slfn11 as a biomarker for detecting the occurrence of ep... |
|
|
Invention
|
Anti-axl antibodies. Antibodies characterized by their variable sequences/CDRs which specifically... |
|
|
Invention
|
Anti-axl antibodies. Antibodies which specifically bind to the Ax I protein are described. Also d... |
|
|
Invention
|
Anti-axl antibodies. Antibodies characterized by their variable sequences /CDRs which specificall... |
|
2014
|
Invention
|
Use of kinase inhibitors. The invention provides a compound for use for treating, preventing or m... |
|
2013
|
Invention
|
Methods for creating and identifying functional rna interference elements. The invention relates ... |
|
|
Invention
|
Methods of detecting akt3 and administering ax1 inhibitor. The use of Akt3 as a biomarker for det... |
|
|
Invention
|
Use of akt3 as a biomarker for detecting the occurrence of epithelial-to-mesenchymal transition. ... |
